Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Saibah Chohan"'
Autor:
Marianne Uguen, Magalie Hilton, Mufiza Farid-Kapadia, Asim Datye, Saibah Chohan, Claudia Carlucci, Mark Dixon, Markus Elze, Yingjia Chen, Kit Wun Kathy Cheung, Rucha Sane, Maoxia Zheng, YounJeong Choi
Publikováno v:
Journal of Biopharmaceutical Statistics. :1-12
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::940c7805da481a9cc3fb88ef0305e553
https://doi.org/10.1080/10543406.2022.2162071
https://doi.org/10.1080/10543406.2022.2162071
Autor:
Ami V Desai, Giles W Robinson, Karen Gauvain, Ellen M Basu, Margaret E Macy, Luke Maese, Nicholas S Whipple, Amit J Sabnis, Jennifer H Foster, Suzanne Shusterman, Janet Yoon, Brian D Weiss, Mohamed S Abdelbaki, Amy E Armstrong, Thomas Cash, Christine A Pratilas, Nadège Corradini, Lynley V Marshall, Mufiza Farid-Kapadia, Saibah Chohan, Clare Devlin, Georgina Meneses-Lorente, Alison Cardenas, Katherine E Hutchinson, Guillaume Bergthold, Hubert Caron, Edna Chow Maneval, Amar Gajjar, Elizabeth Fox
Publikováno v:
Neuro-Oncology. 24:1776-1789
Background Entrectinib is a TRKA/B/C, ROS1, ALK tyrosine kinase inhibitor approved for the treatment of adults and children aged ≥12 years with NTRK fusion-positive solid tumors and adults with ROS1 fusion-positive non–small-cell lung cancer. We
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03639f7f0384b3824fab7613aeb1e8fa
https://doi.org/10.1093/neuonc/noac087
https://doi.org/10.1093/neuonc/noac087
Autor:
Alexandru Eniu, V. McNally, Ž. Zvirbule, Jung Ho Sohn, Yibing Yan, S.-B. Kim, Matthew Wongchenko, Adam Brufsky, David Miles, Saibah Chohan, Jeroen Mebis, Sherene Loi, R. Amin
Background: Resistance to standard chemotherapy in metastatic triple-negative breast cancer (mTNBC) is associated with upregulation of the mitogen-activated protein kinase (MAPK) pathway. Cobimetinib, an MAPK/extracellular signal-regulated kinase (ME
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd79d91b0da371afcc23e33953fb7318
http://hdl.handle.net/1942/34426
http://hdl.handle.net/1942/34426
Autor:
Thomas Cash, Amit J. Sabnis, Kellie J. Nazemi, Saibah Chohan, Jennifer Foster, Ellen M. Basu, Mohamed S. AbdelBaki, Christine A. Pratilas, Margaret E. Macy, Luke Mease, Katherine E. Hutchinson, Ami V. Desai, Janet M. Yoon, Karen Gauvain, Guillaume Bergthold, Alison Cardenas, Suzanne Shusterman, Giles W. Robinson, Amar Gajjar, Brian Weiss
Publikováno v:
Neuro-Oncology
STARTRK-NG (phase 1/2) is evaluating entrectinib, a CNS-penetrant oral, TRK/ROS1/ALK tyrosine kinase inhibitor, in patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::30c5c75f4b5c0b7bddcfcd8f1fbe7248
https://doi.org/10.1093/neuonc/noaa222.293
https://doi.org/10.1093/neuonc/noaa222.293
Autor:
Sung-Bae Kim, V. McNally, Saibah Chohan, Sherene Loi, David Miles, Joohyuk Sohn, Matthew Wongchenko, Luc Dirix, Jeroen Mebis, Francisco Carabantes, Adam Brufsky, Zanete Zvirbule, Alexandru Eniu, Yann Izarzugaza, Reena Amin
Publikováno v:
Journal of Clinical Oncology. 37:1013-1013
1013 Background: COLET showed that the addition of C (MEK1/2 inhibitor) to P resulted in an increased ORR (38%; Brufsky, SABCS 2017); IMpassion130 demonstrated clinical benefit with the combination of PD-L1 inhibitor A and nP as 1L tx for pts with mT
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::684c45b4110929ec146749b053858355
https://doi.org/10.1200/jco.2019.37.15_suppl.1013
https://doi.org/10.1200/jco.2019.37.15_suppl.1013